BiographyAbdulrahman Kehail, completed his Bachelor's degree in Biomedical Engineering from the Hashemite University, Jordan, in 2009, then was awarded a scholarship to pursue his Master's degree in Biomedical Engineering and Biotechnology at the University of Massachusetts, where he graduated in 2012. He then started his career in the Biotechnology/Pharma field at Biogen, Cambridge, MA, USA, for 2 years. During his time at Biogen, he realized his passion in biotech, and he needs to improve his scientific knowledge in the field, therefore, he started to apply for PhD programs and labs that excel in this field. He landed a scholarship and a research assistant opportunity with Prof. Christopher Brigham at the University of Massachusetts to work on cell culture and fermentation optimization to produce proteins and bio-plastics during his PhD, where his degree in Bioengineering and Biotechnology was awarded in 2017. Since then, he joined several pharma giants as Amgen, Shire, and Takeda as a Scientist in the Process Development team optimizing biological drugs production, such as monoclonal antibodies, enzymes, and cell therapy, in labs and large manufacturing settings. Abdulrahman has several publications, and was granted numerous awards.
Current Technologies Using Different Modalities (Methods) in Biological Drugs Production, Such as Cell, Gene, and Enzyme Replacement Therapy.Biological drugs production using different advancements; cell therapy, gene therapy, and enzyme replacement therapy, is a fast paced advancing topic which aims to limit rare and chronic diseases to as minimal as possible. Thanks to these technologies, many biotech/pharma start ups around the world are racing to cure diseases that were considered incurable few decades ago. This topic will focus on current advancements and research, and how to apply engineering principles in biological drugs production process.